skip to Main Content

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers

Newsfeed image, light gray text on dark gray background
Brian M. Wolpin, MD, MPH, associate professor of medicine, Harvard Medical School, director, Gastrointestinal (GI) Cancer Center, co-director, Pancreas and Billary Tumor Center, Robert T. and Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978). [/subhead}

The study evaluated the efficacy of using a DNA methylation–based circulating cell-free DNA (cfDNA) assay to detect cancers specific to regions of the GI tract. Watch here . . .

Back To Top